Tozasertib

Tozasertib Struktur
639089-54-6
CAS-Nr.
639089-54-6
Englisch Name:
Tozasertib
Synonyma:
VE465;VX 680;VX-860;CS-176;VE 465;VE-465;MK 0457;Tozasertib;L-001281814;VX-680/MK-0457
CBNumber:
CB51513746
Summenformel:
C23H28N8OS
Molgewicht:
464.59
MOL-Datei:
639089-54-6.mol

Tozasertib Eigenschaften

Schmelzpunkt:
248-253°C (dec.)
Dichte
1.40±0.1 g/cm3(Predicted)
storage temp. 
2-8°C
Löslichkeit
Soluble in DMSO (up to 100 mg/ml).
pka
14.09±0.70(Predicted)
Aggregatzustand
powder
Farbe
white to beige
Stabilität:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H302 Gesundheitsschädlich bei Verschlucken. Akute Toxizität oral Kategorie 4 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P270, P301+P312, P330, P501
Sicherheit
P280 Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.
P305+P351+P338 BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

Tozasertib Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

The Aurora kinases (A, B, and C) are a family of serine-threonine kinases that regulate various stages of mitotic function. With significant roles in cell cycle and cell division, Aurora kinase gene amplification and overexpression are linked to tumorigenesis. MK-0457 is a potent pan-Aurora kinase inhibitor but favors Aurora A (Ki = 0.6 nM) over Aurora B (Ki = 18 nM) or Aurora C (Ki = 4.6 nM). It shows selectivity against a panel of more than 190 different protein kinases. MK-0457 effectively inhibits proliferation of several different cell lines of clear cell renal carcinoma (IC50s = <10 μM) and blocks the growth of tumors in a rodent model of cancer (80 mg/kg), inhibiting histone H3 phosphorylation and increasing apoptosis. By depleting Aurora activity, MK-0457 disrupts bipolar spindle formation during mitosis, arresting cell cycle progression at the G2/M phase.

Chemische Eigenschaften

White Solid

Verwenden

Tozasertib is used as a multikinase inhibitor once used for cancer treatment.

Tozasertib Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Tozasertib Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 196)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Capot Chemical Co.,Ltd.
571-85586718 +8613336195806
sales@capotchem.com China 29797 60
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32686 60
Hubei xin bonus chemical co. LTD
86-13657291602
linda@hubeijusheng.com CHINA 22968 58
BOC Sciences
+1-631-485-4226
inquiry@bocsci.com United States 19553 58
CONIER CHEM AND PHARMA LIMITED
+8618523575427
sales@conier.com China 49391 58
career henan chemical co
+86-0371-86658258 15093356674;
factory@coreychem.com China 29826 58
SIMAGCHEM CORP
+86-13806087780
sale@simagchem.com China 17367 58
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000
marketing@targetmol.com United States 19892 58
ANHUI WITOP BIOTECH CO., LTD
+8615255079626
eric@witopchemical.com China 23556 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250
1026@dideu.com China 28098 58

639089-54-6()Verwandte Suche:


  • Cyclopropane carboxylic acid {4-[4-(4-methyl-piperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino) -pyrimidin-2ylsulphanyl]-phenyl}-amide
  • VX-680/MK-0457
  • N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)-6-(1-methylpiperidin-4-ylamino)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide
  • MK 0457
  • N-[4-[[4-(4-Methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide
  • Tozasertib
  • VX 680
  • Cyclopropanecarboxamide, N-(4-((4-(4-methyl-1-piperazinyl)-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-pyrimidinyl)thio)phenyl)-
  • N-(4-(4-(5-Methyl-1H-pyrazol-3-ylamino)-6-(1-methylpiperidin-4-ylamino)pyrimidin-2-ylthio)phen
  • N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide
  • Tozasertib N-[4-[[4-(4-Methyl-1-piperazinyl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]thio]phenyl]cyclopropanecarboxamide
  • VX-680(Tozasertib)
  • Tozasertib(MK-0457,VX-680)
  • VX-860
  • Cyclopropanecarboxylic acid N-(4-((4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-yl)sulfanyl)phenyl)amide
  • L-001281814
  • Tozasertib/VX-680
  • N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-(4-methylpiperazin-1-yl)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide
  • VX-680 (MK-0457)(Tozasertib)
  • Tozasertib£VX680£MK0457
  • Tozasertib Free Base
  • N-[4-[[4-(4-Methylpiperazin-1-yl)-6-[(5-Methyl-1H-pyrazol-3-yl)aMino]pyriMidin-2-yl]thio]phenyl]cyclopropanecarboxaMide
  • VX-680 (Tozasertib, MK-0457)
  • VX680;MK0457;VX 680 (MK 0457;TOZASERTIB)
  • CS-176
  • VE 465
  • VE465
  • VE-465
  • VX680; VX 680; VX-680; MK0457; MK 0457; MK-0457; VE465; VE-465; VE 465; TOZASERTIB
  • TOZASERTIB;MK-0457;MK0457;VX680;VX 680;MK 0457
  • N-[4-({4-[(3-METHYL-1H-PYRAZOL-5-YL)AMINO]-6-(4-METHYLPIPERAZIN-1-YL)PYRIMIDIN-2-YL}SULFANYL)PHENYL]CYCLOPROPANECARBOXAMIDE
  • tozasertib (MK-0457)
  • MK-0457,Tozasertib
  • Tozasertib USP/EP/BP
  • N-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide
  • MK-0457 Tozasertib VX-680
  • 639089-54-6
  • C24H30N8OS
  • C23H28N8OS
  • Inhibitors
  • A multikinase inhibitor.
  • Inhibitor
  • Aromatics
  • Heterocycles
  • Intermediates & Fine Chemicals
  • Mutagenesis Research Chemicals
  • Pharmaceuticals
Copyright 2019 © ChemicalBook. All rights reserved